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Abstract 
A new group of 5,5-diarylhydantoin derivatives bearing a methylsulfonyl COX-2 
pharmacophore at the para position of the C-5 phenyl ring were designed and 
synthesized as selective COX-2 inhibitors. In vitro COX-1/COX-2 inhibition 
structure-activity relationships identified  5-[4-(methylsulfonyl)phenyl]-5-phenyl-
hydantoin (4) as a highly potent and selective COX-2 inhibitor (COX-2 IC50 = 
0.077 µM; selectivity index > 1298). It was more selective than the reference 
drug celecoxib (COX-2 IC50 = 0.060 µM; selectivity index = 405). A molecular 
modeling study where 4 was docked in the binding site of COX-2 indicated that 
the p-MeSO2 COX-2 pharmacophore group on the C-5 phenyl ring is oriented in 
the vicinity of the COX-2 secondary pocket. The results of this study showed 
that the type of substituent on the N-3 hydantoin ring substituent is important for 
COX-2 inhibitory activity. 
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Introduction 
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely utilized for the treatment of 
various inflammatory conditions such as rheumatic fever, rheumatoid arthritis and 
osteoarthritis. These drugs are competitive inhibitors of cyclooxygenase (COX), a rate 
limiting enzyme that mediates the bioconversion of arachidonic acid to inflammatory 
prostaglandins (PGs) [1, 2]. COX is a membrane-bound heme protein which exists at least 
in two different isoforms, COX-1 and COX-2 [3]. COX-1, described as a "housekeeping" 
enzyme, is normally expressed in the gastrointestinal tract, kidneys and platelets. Under 
the influence of COX-1, prostaglandins maintain the integrity of the gastric mucosa, 
mediate normal platelet function and regulate renal blood flow [4]. The isoenzyme COX-2 
is primarily associated with inflammation. Cytokines and growth factors increase the 
expression of COX-2, mainly at inflammatory sites, producing prostaglandins that mediate 
inflammation, pain and fever [5].  However, because NSAIDs inhibit both isoforms of 
cyclooxygenase (COX) their use is often accompanied by gastrointestinal side effects and 
renal function suppression [6]. It is known that selective COX-2 inhibitors can provide anti-
inflammatory agents devoid of the undesirable effects associated  with classical non 
selective NSAIDs. Moreover, recent studies indicating the place of COX-2 inhibitors in the 
prevention of several cancer types such as colon, breast, lung and prostate cancers [7–10] 
and neurodegenerative diseases such as Parkinson [11] and Alzheimer’s [12] diseases 
still continues to attract investigations on development of COX-2 inhibitors. 1,2-Diaryl-
heterocycles, and other central ring pharmacophore templates, have been extensively 
studied as the most important selective COX-2 inhibitors. Several series of selective COX-
2 inhibitors belonging to the 1,2-diaryl class of compounds containing different heterocyclic 
and carbocyclic moieties as a central scaffold have been developed. All these tricyclic 
molecules possess a characteristic sulfonyl group  such as a para-SO2NH2  or a para-
SO2Me substituent on one of the phenyl rings which plays an important role on COX-2 
selectivity [13]. Celecoxib and rofecoxib are two well-known selective COX-2 inhibitors 
belong to COXIBs class [14, 15]. However, the market withdrawal of some COXIBs such 
as rofecoxib due to increase the risk of heart attack and cardiovascular side effects [16] 
encourages the researchers to explore new selective COX-2 inhibitors to evaluate their 
effects and may improve the safety profiles. In addition, recent studies have suggested 
that rofecoxib’s adverse cardiac events may not be a class effect but rather related to its 
particular chemical structure [17]. For this reason novel scaffolds with high selectivity for 
COX-2 inhibition need to be found and evaluated for their biological activities. In this 
regard, several selective COX-2 inhibitors with geminal diaryl groups (see structures A, B) 
have been reported that exhibited considerable potency and selectivity on COX-2 inhibition 
[18]. As part of our research program, aimed at discovering new selective COX-2 
inhibitors, we focused our attention on the synthesis, COX inhibitory and some molecular 
modeling studies of 5,5-diarylhydantoin  derivatives possessing a methylsulfonyl COX-2 
pharmacophore at the para position of the C-5 phenyl ring. In these designed compounds 
we utilized geminal diarylhydantoin as new scaffold of COX-2 inhibitors.   Design, Synthesis and Biological Evaluation of New 5,5-Diarylhydantoin Derivatives as Selective … 451 
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Fig. 1.   Some representative examples of selective COX-2 inhibitors and our designed 
compounds. 
Results and Discussion 
The target 5,5-diarylhydantoin derivatives 4–8 were synthesized via the route outlined in 
Scheme 1. As illustrated in the Scheme 1, 1-[4-(methylthio)phenyl]-2-phenylethanone (1) 
was synthesized by Friedel-Crafts acylation of thioanisole with phenylacetyl chloride (yield 
75%) [19]. Oxidation of 1 with selenium dioxide in dioxane-water under reflux condition 
gave 1-[4-(methylthio)phenyl]-2-phenylethane-1,2-dione (2) (yield 92%) [19]. Reaction of 2 
with urea under alkaline condition afforded 5-[4-(methylsulfanyl)phenyl]-5-phenylhydantoin 
(3, yield: 37%) [20]. Oxidation of 3 with oxone in THF-water gave the oxidized methyl-
sulfonyl compound 4  (yield 67%) [21].The alkylated hydantoin derivatives 5–8  were 
prepared using an appropriate alkyl halide in alkaline ethanol (yield: 27–54%) [22]. The 
purity of all products was determined by thin layer chromatography using several solvent 
systems of different polarity. All compounds were pure and stable. The compounds were 
characterized by NMR, infrared, mass spectrometry and CHN analysis.  452  A. Zarghi et al.:   
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Sch. 1.   Reagents and conditions: (a) AlCl3, CH2Cl2, 0–25 °C, 2 h (b) SeO2, dioxane-
H2O, reflux, 1 h (c) urea, 30% aqueous NaOH, EtOH, reflux, 3 h (d) oxone, 
THF-H2O, 25 °C, 3 h (e) RI or RBr, K2CO3/DMF, 10–30 min. 
All of the prepared 5,5-diarylhydantoin derivatives having different substituents at the N-3 
hydantoin ring were evaluated to investigate the effect of different alkyls on COX-2 
selectivity and potency. The ability of the 5,5-diarylhydantoin 4–8 to inhibit the COX-1 and 
COX-2 isozymes was determined using chemiluminescent enzyme assays (see enzyme 
inhibition data in Table 1.) according to our previously reported method [23]. In vitro COX-
1/COX-2 inhibition studies showed that all compounds 4–8 were selective inhibitors of the 
COX-2 isozyme with IC50 values in the highly potent 0.077 to 0.171 μM range, and COX-2 
selectivity indexes (S.I.) in the 70.2 to > 1298 range. The relative COX-2 selectivity profiles 
for the 5,5-diarylhydantoin derivatives 4–8, with respect to the N-3 substituent (R) was H > 
Me > Et> Allyl > Pr. SAR data (IC50 values) acquired by determination of the in vitro ability 
of the title compounds to inhibit the COX-1 and COX-2 isozymes showed that the COX 
inhibition is sensitive to the size of substituent at the N-3 hydantoin ring. These data 
showed that the type of substituent attached to N-3 of hydantoin ring affected selectivity for 
COX-2 inhibitory activity. Accordingly, compounds having larger groups at the N-3 central 
ring showed less selectivity for COX-2 isozyme that can be explained by steric parameter. 
However, among the 5,5-diarylhydantoin derivatives, compound 4 with no substituent at 
N-3 hydantoin ring exhibited the highest COX-2 inhibitory selectivity (COX-2 IC50 = 0.077 
µM; SI > 1298) that was more selective than the reference drug celecoxib (COX-2 IC50 = 
0.060 µM; SI = 405). In addition, our results showed that the unsubstituted compound 4 
had significantly higher selectivity index compared with the alkylated analogues 5–8. This 
difference is mainly due to poor affinity of compound 4 for COX-1 (COX-1 IC50 > 100 µM;   Design, Synthesis and Biological Evaluation of New 5,5-Diarylhydantoin Derivatives as Selective … 453 
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SI > 1298) comparison to alkylated hydantoins which showed more activities for COX-1 
inhibition. Our in vitro enzyme inhibition data also showed that the size of N-3-alkyl is 
important for COX-1 inhibitory activity and therefore it can affect the selectivity index. In 
addition to steric parameter, the unsubstituted hydantoin 4  is more acidic than the 
alkylated compounds and therefore it can be as keto-enol forms. This effect may cause 
different tautomer forms for compound 4 and may explain its different interaction in COX-1 
active site relative to its 3-alkylated derivatives. Accordingly, the binding interactions of the 
most potent and selective COX-2 inhibitor compound (4) within the COX-2 binding site 
were investigated. The most stable enzyme-ligand complex of 5-(4-methylsulfonyl) phenyl-
5-phenyl-hydantoin (4) possessing a MeSO2 COX-2 pharmacophore at para position of 
C-5 phenyl ring within the COX-2 binding site (Fig. 2) shows that the p-MeSO2–phenyl 
moiety is oriented towards the COX-2 secondary pocket (Arg
513, Phe
518 and Val
523). One of 
the  O-atoms of p-MeSO2  substituent forms a hydrogen binding interaction with amino 
group of Arg
513 (distance = 4.6 A
o) whereas the other O-atom is about 3.5 Å away from NH 
of Arg
513. In addition, a hydrogen bonding interaction can form between the NH group at 
position 3 of hydantoin ring and nitrogen atoms of Arg
120 (distance = 4.8 Å) which may 
explain the high potency and selectivity of compound 4. In this regard, a similar molecular 
modeling study was performed where compounds 4 and 5 were docked in the COX-1 
binding site (Fig. 3) to explain the difference COX-1 activities of compound 4 and alkylated 
compounds such as 5. Our results indicated that the most stable enzyme-ligand complex 
of N-3-methyl-5-(4-(methylsulfonyl)phenyl)-5-phenylhydantoin (5) well docked in the COX-
1 active site whereas the unsubstituted compound 4 was not docked into the active site of 
COX-1 as well as its alkylated analogue 5. These results can facilitate the interpretation of 
in vitro enzyme inhibition structure-activity data. 
Tab 1.   In vitro COX-1 and COX-2 enzyme inhibition assay data for 5,5-diarylhydantoin 
derivatives 4–8 
N
N
H
MeO2S
R
O
O
 
Compound  R  IC50 (μM)
a  Selectivity 
index (SI)
b  COX-1  COX-2 
4  H  >100  0.077  >1298 
5  Me  22.69  0.081  280.1 
6  Et  20.21  0.098  206.2 
7  Pr  12.01  0.171  70.2 
8  Allyl  14.96  0.099  151.1 
Celecoxib  –  24.3  0.060  405 
a Values are means of two determinations acquired using an 
ovine COX-1/COX-2 assay kit and the deviation from the mean is 
< 10% of the mean value. 
b In vitro COX-2 selectivity index 
(COX-1 IC50/ COX-2 IC50). 
 454  A. Zarghi et al.:   
Sci Pharm. 2011; 79: 449–460 
 
Fig. 2.   Docking of 4 in the active site of murine COX-2.  
Conlcusion 
This study indicates that (i) the hydantoin ring is a suitable scaffold to design COX-2 
inhibitors, (ii) COX-2 selectivity index is sensitive to the type of N-3 hydantoin substituent, 
and (iii) 5-[4-(methylsulfonyl)phenyl]-5-phenyl-hydantoin  (4) exhibited high COX-2 
inhibitory potency and selectivity. 
Experimental 
Chemistry 
All chemicals and solvents used in this study were purchased from Merck AG and Aldrich 
Chemical. Melting points were determined with a Thomas–Hoover capillary apparatus. 
Infrared spectra were acquired using a Perkin Elmer Model 1420 spectrometer. A Bruker 
FT-500 MHz instrument (Bruker Biosciences, USA) was used to acquire 
1HNMR spectra 
with TMS as internal standard. Chloroform-D and DMSO-D6  were used as solvents. 
Coupling constant (J) values are estimated in hertz (Hz) and spin multiples are given as s 
(singlet), d (double), t (triplet), q (quartet), m (multiplet), and br (broad). Low-resolution 
mass spectra were acquired with a MAT CH5/DF (Finnigan) mass spectrometer that was 
Tyr
348 
Trp
387 
Phe
518 
Gly
519 
Arg
513 
Tyr
355 
Arg
120 
Tyr
385 
Ser
530 
Val
523 
Ala
527   Design, Synthesis and Biological Evaluation of New 5,5-Diarylhydantoin Derivatives as Selective … 455 
Sci Pharm. 2011; 79: 449–460 
coupled online to a Data General DS 50 data system. Electron-impact ionization was 
performed at an ionizing energy of 70 eV with a source temperature of 250 °C. A 6410 
Agilent LCMS triple quadrupole mass spectrometer (LCMS) with an electrospray ionization 
(ESI) interface was also used for molecular weight measurement. Microanalyses, 
determined for C, H, and N were within ± 0.4% of theoretical values. 
 
Fig. 3.   Docking of 4 (in blue) and 5 (in pink) in the active site of murine COX-1.  
1-[4-(Methylsulfanyl)phenyl]-2-phenylethanone (1) 
Phenacetyl chloride (4 ml, 30.2 mmol) was added to a suspension of anhydrous aluminum 
chloride (4.2 g, 31.6 mmol) in dry dichloromethane (50 ml) under argon atmosphere at 
0 °C. After stirring the reaction mixture for 30 min, thioanisole (3 ml, 24 mmol) was slowly 
added during 15 min. After keeping the mixture at this temperature for 2 hrs, it was allowed 
to stir at room temperature overnight. Then the mixture was poured over crushed ice and 
extracted with dichloromethane (3×50 ml), and the combined organic layer after washing 
with water was dried by anhydrous MgSO4  and evaporated. The solid product was 
recrystalized in ethanol. Yield: 75%; mp: 97–98 °C; IR (KBr): ν (cm
−1) 1685 (CO), 
1HNMR 
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(CDCl3): δ (ppm) 2.52 (s, 3H, SMe), 4.22 (s, 2H, CH2), 7.21–7.33 (m, 7H, Phenyl H2-H6 & 
4-methylthiophenyl H3 & H5), 7.91 (d, 2H, 4-methylthiophenyl H2 & H6, J=8.4 Hz). LC-MS 
(ESI) m/z: 243.1 (M+1) (100). 
1-[4-(Methylsulfanyl)phenyl]-2-phenylethane-1,2-dione (2) 
Selenium dioxide (2.5 g, 22.5 mmol) was dissolved in a mixture of 1,4-dioxane-water 
(50 ml, 48:2). The 1,4-dioxane solution of 1 (2.5 g, 10.3 mmol), was added to the reaction 
mixture and refluxed overnight. The precipitated selenium was filtered off and the filtrate 
was poured over ice water. After extraction with ethyl acetate (3×50 ml) the combined 
organic phase was washed with water, dried and evaporated to get yellow solid and 
crystallized in ethanol. Yield: 92%; mp: 58–59 °C; IR (KBr): ν (cm
−1) 1675, 1586 (CO); 
1HNMR (CDCl3): δ (ppm) 2.62 (s, 3H, SMe), 7.13–7.42 (m, 7H, Phenyl H2-H6 & 4-methyl-
thiophenyl H3 & H5), 8.06 (d, 2H, 4-methylthiophenyl H2 & H6, J=8.3 Hz); LC-MS (ESI) m/z: 
257.1 (M+1) (100). 
5-[4-(Methylsulfanyl)phenyl]-5-phenylimidazolidine-2,4-dione 
(5-[4-(Methylthio)phenyl]-5-phenylhydantoin, 3) 
A solution of 2 (1.5 g, 5.8 mmol) and urea (0.4 g, 6.7 mmol) in 30% aqueous sodium 
hydroxide and ethanol (50 ml) acid was refluxed for 3 hours. The reaction mixture was 
then cooled and poured into ice-cold water. The mixture was filtered and the filtrate was 
acidified with concentrated hydrochloric acid, cooled in ice-water and the precipitated 
product was filtered under vacuum. After washing with water, the product was crystallized 
in ethyl acetate Yield: 37%; mp: 115–116 °C; IR (KBr): ν (cm
−1) 3568, 3287 (NH), 1709 
(CO)
, 
1HNMR (CDCl3): δ (ppm) 2.42 (s, 3H, SMe), 7.24–7.32 (m, 7H, Phenyl H2-H6 & 4-
methylthiophenyl H3 & H5), 7.36 (d, 2H, 4-methylthiophenyl H2 & H6, J=8.2 Hz); LC-MS 
(ESI) m/z: 299.1 (M+1) (100); Anal. Calcd. for C16H14N2O2S: C, 64.41; H, 4.73; N, 9.39. 
Found: C, 64.62; H, 4.99; N, 9.22. 
5-[4-(Methylsulfonyl)phenyl]-5-phenylimidazolidine-2,4-dione 
(5-[4-(Methylsulfonyl)phenyl]-5-phenylhydantoin, 4) 
0.5 g (1.7 mmol) of hydantoin 3 was dissolved in 10 ml THF and 2.5 g oxone in THF/water 
was added. The mixture was stirred at room temperature for 4 hours, after evaporation of 
THF, the residue was extracted with ethyl acetate and dried with sodium sulfate and then 
evaporated. The product was recrystallized in ethanol. Yield: 67%; mp: 223–224 °C; IR 
(KBr): ν (cm
−1) 3210, 3100 (NH), 1727, 1706 (CO),1307, 1154 (SO2); 
1HNMR (CDCl3): δ 
(ppm) 3.18 (s, 3H, SO2Me), 7.29–7.40 (m, 5H, Phenyl), 7.59 (d, 2H, 4-methylsufonylphenyl 
H2 & H6, J=8.4 Hz), 7.97 (d, 2H, 4-methylsufonylphenyl H3 & H5, J=8.4 Hz); 9.42 (s, 1H, 
NH), 11.23 (s, 1H, NH); 
13C-NMR (CDCl3): δ 44.1, 71.1, 126.1, 128.3, 128.7, 129.4, 129.6, 
136.2, 139.8, 144.9, 157.0, 174.6; LC-MS (ESI) m/z: 331.1 (M+1) (100); Anal. Calcd. for 
C16H14N2O4S: C, 58.17; H, 4.27; N, 8.48. Found: C, 58.33; H, 4.59; N, 8.32. 
General Procedure for the Synthesis of N-3-alkylated hydantoins 5–8 
1 mmol of 4 was dissolved in the suspension of DMF/K2CO3 (1.1 mmol) and 1 mmol of 
alkyl halide (iodomethane, iodoethane, propyl bromide and allyl bromide) was added and 
the mixture was stirred at room temperature until TLC indicated that started material had 
been consumed (the duration of vortex was controlled to avoid alkylation of the second 
nitrogen site). Then, the reaction mixture was added to three volumes of cold water and   Design, Synthesis and Biological Evaluation of New 5,5-Diarylhydantoin Derivatives as Selective … 457 
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extracted with ethyl acetate. The ethyl acetate extracts were washed with 5% NaOH, 
water, and dried over Na2SO4. The solvent was removed and the product crystallized in 
ethanol (yields: 27–54%). 
3-Methyl-5-[4-(methylsulfonyl)phenyl]-5-phenylimidazolidine-2,4-dione 
(N-3-Methyl-5-(4-(methylsulfonyl)phenyl)-5-phenylhydantoin, 5) 
Yield: 29%; mp: 212–214 °C; IR (KBr): ν (cm
−1) 3230 (NH),1707 (CO),1313, 1153 (SO2); 
1HNMR (CDCl3): δ (ppm) 3.09 (s, 3H, CH3), 3.15 (s, 3H, SO2Me), 6.57 (s, 1H, NH), 7.29–
7.44 (m, 5H, Phenyl), 7.69 (d, 2H, 4-methylsufonylphenyl H2 & H6, J=8.4 Hz), 7.98 (d, 2H, 
4-methylsufonylphenyl H3 & H5, J=8.4 Hz); 9.42 (s, 1H, NH), 11.23 (s, 1H, NH); 
13C-NMR 
(CDCl3): δ 29.8, 44.3, 69.4, 126.2, 128.3, 128.5, 129.4, 129.6, 136.5, 139.9, 144.5, 156.7, 
163.1; LC-MS (ESI) m/z: 345.1 (M+1) (100); Anal. Calcd. for C17H16N2O4S: C, 59.29; H, 
4.68; N, 8.13. Found: C, 59.53; H, 4.89; N, 8.01. 
3-Ethyl-5-[4-(methylsulfonyl)phenyl]-5-phenylimidazolidine-2,4-dione 
(N-3-Ethyl-5-(4-(methylsulfonyl)phenyl)-5-phenylhydantoin, 6) 
Yield: 54%; mp: 91–92 °C; IR (KBr): ν (cm
−1) 3302 (NH),1709 (CO),1310, 1148 (SO2); 
1HNMR (CDCl3): δ (ppm) 1.30 (t, 3H, CH3, J=7.1 Hz), 3.10 (s, 3H, SO2Me), 3.70 (q, 2H, 
CH2,  J=7.1 Hz), 6.79 (s, 1H, NH), 7.29–7.43 (m, 5H, Phenyl), 7.69 (d, 2H, 4-methyl-
sufonylphenyl H2 & H6, J=8.4 Hz), 7.98 (d, 2H, 4-methylsufonylphenyl H3 & H5, J=8.4 Hz); 
13C-NMR (CDCl3):  δ  12.6, 35.8, 44.2, 69.6, 126.3, 128.3, 128.6, 129.5, 129.7, 136.6, 
139.9, 144.5, 156.7, 163.1; LC-MS (ESI) m/z: 359.1 (M+1) (100); Anal. Calcd. for 
C18H18N2O4S: C, 60.32; H, 5.06; N, 7.82. Found: C, 60.12; H, 5.31; N, 8.05. 
5-[4-(Methylsulfonyl)phenyl]-5-phenyl-3-propylimidazolidine-2,4-dione 
(5-(4-(Methylsulfonyl)phenyl)-5-phenyl-N-3-propyl-hydantoin, 7) 
Yield: 47%; mp: 82-83 °C; IR (KBr): ν  (cm
−1) 3302 (NH),1700 (CO),1310, 1150 (SO2); 
1HNMR (CDCl3): δ (ppm) 0.95 (t, 3H, CH3, J=7.4 Hz), 1.72 (m, 2H, CH2), 3.09 (s, 3H, 
SO2Me), 3.60 (t, 2H, CH2N, J=7.3 Hz), 6.38 (s, 1H, NH), 7.29–7.43 (m, 5H, Phenyl), 7.69 
(d, 2H, 4-methylsufonylphenyl H2 & H6, J=8.4 Hz), 7.98 (d, 2H, 4-methylsufonylphenyl H3 & 
H5, J=8.4 Hz); 
13C-NMR (CDCl3): δ 11.2, 19.6, 44.1, 44.4, 69.1, 126.4, 128.3, 128.7, 129.5, 
129.7, 136.7, 139.7, 144.7, 156.6, 162.1;  LC-MS (ESI) m/z: 373.1 (M+1) (100); Anal. 
Calcd. for C19H20N2O4S: C, 61.27; H, 5.41; N, 7.52. Found: C, 61.52; H, 5.01; N, 7.85. 
5-[4-(Methylsulfonyl)phenyl]-5-phenyl-3-(prop-2-en-1-yl)imidazolidine-2,4-dione 
(N-3-Allyl-5-(4-(methylsulfonyl)phenyl)-5-phenylhydantoin, 8) 
Yield: 27%; mp: 129–130 °C; IR (KBr): ν (cm
−1) 3322 (NH),1704 (CO),1312, 1152 (SO2); 
1HNMR (CDCl3): δ (ppm) 3.10 (s, 3H, SO2Me), 4.20 (d, 2H, CH2N, J=5.6 Hz), 5.22 (d, 2H, 
CH2, J=11.3 Hz), 5.85 (m, 1H, CH), 6.55 (s, 1H, NH), 7.29–7.42 (m, 5H, Phenyl), 7.69 (d, 
2H, 4-methylsufonylphenyl H2 & H6, J=8.4 Hz), 7.94 (d, 2H, 4-methylsufonylphenyl H3 & 
H5, J=8.4 Hz); 
13C-NMR (CDCl3): δ 44.1, 69.3, 117.1, 126.3, 128.2, 128.6, 129.4, 129.7, 
134.7,  136.8, 139.9, 144.7, 156.8, 161.9;  LC-MS (ESI) m/z: 371.1 (M+1) (100); Anal. 
Calcd. for C19H18N2O4S: C, 61.61; H, 4.90; N, 7.56. Found: C, 61.76; H, 5.11; N, 7.25. 
Docking Studies 
Docking studies were performed using Autodock software Version 3.0.5. The coordinates 
of the X-ray crystal structure of the selective COX-2 inhibitor SC-558 bound to the murine 458  A. Zarghi et al.:   
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COX-2 enzyme was obtained from the RCSB Protein Data Bank (1cx2) and hydrogens 
were added. The ligand molecules were constructed using the Builder module and were 
energy minimized for 1000 iterations reaching a convergence of 0.01 kcal/mol Å.  The 
energy minimized ligands were superimposed on SC-558 in the PDB file 1cx2 after which 
SC-558 was deleted. The purpose of docking is to search for favorable binding 
configuration between the small flexible ligands and the rigid protein. Protein residues with 
atoms greater than 7.5 Å from the docking box were removed for efficiency. These docked 
structures were very similar to the minimized structures obtained initially. The quality of the 
docked structures was evaluated by measuring the intermolecular energy of the ligand-
enzyme assembly [24,25]. 
Biological Assay 
The ability of the test compounds listed in Table 1 to inhibit ovine COX-1 and COX-2 (IC50 
value,  μM)  was  determined  using  chemiluminescent  enzyme  assays  kit  (Cayman 
Chemical, Ann Arbor, MI, USA) according to our previously reported method [23]. 
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